Startup profile · funding coverage
Aradigm
Benefits platform enabling sustainable employer access to cell and gene therapies.
Stage
series a
Status
private
Coverage
full
Why Aradigm is interesting
Public benefit corporation pooling CGT risk for employers and payors — founded by Will Shrank (ex-Humana, CMS, a16z venture partner) to solve million-dollar therapy affordability.
Key facts
- Series A (2025): co-led by Frist Cressey and Morgan Health with a16z; Two Sigma Ventures and First Round named in reporting (Endpoints News)
- Seed (2024): a16z led at inception (a16z announcement)
- Model: PBC pooling CGT risk for employer-sponsored health plans (Aradigm site)
- Co-investors not in VCT directory: Frist Cressey Ventures, Morgan Health
Investors in our directory
Funds linked from Aradigm's profile — open a fund page for stage focus and related deal articles.
Industries
Healthtech Biotech & Life Sciences
Industry hub pages are rolling out from our fund-derived baseline taxonomy.
Related funding articles
Venture Capital Tracker pieces that cover Aradigm's financing or category context.
FAQs about Aradigm
Funding context and why this company shows up in venture coverage.
Aradigm helps employers and health plans sustainably cover cell and gene therapies by pooling risk and designing benefits that make million-dollar CGTs accessible without unpredictable single-case costs.
Directory-linked investors include Andreessen Horowitz (/fund/andreessen-horowitz), First Round (/fund/first-round), and Two Sigma Ventures (/fund/two-sigma-ventures). Frist Cressey and Morgan Health co-led the Series A.
Aradigm launched in 2024 with a16z-led seed funding and raised a Series A in 2025 — an early-stage healthtech company.
Approved CGTs can cost $1M+ per patient. Employers struggle to budget for rare but catastrophic claims — Aradigm's pooling model addresses the affordability gap as more CGTs reach market.
No — Aradigm remains a private public benefit corporation as of July 2026.
Last updated: 2026-07-24